R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者中肌肉减少症的预后价值：一项系统评价和荟萃分析

Prognostic Value of Sarcopenia in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A Systematic Review and Meta-Analysis.

作者信息

Xu Xin-Tian, He Dong-Liang, Tian Meng-Xing, Wu Hui-Jing, Jin Xin

机构信息

Department of Pharmacy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Department of Nutrition, Hengyang Central Hospital, Hengyang, China.

出版信息

Front Nutr. 2022 Feb 25;9:816883. doi: 10.3389/fnut.2022.816883. eCollection 2022.

OBJECTIVE

Several studies have reported conflicting results regarding the association between sarcopenia and outcomes in patients with diffuse large B-cell lymphoma (DLBCL). This meta-analysis aimed to evaluate the prognostic value of sarcopenia in patients with DLBCL.

METHODS

PubMed, Embase, and Cochrane Library databases were searched to identify trials exploring the association between sarcopenia and prognosis in patients with DLBCL treated with chemotherapy. A meta-analysis of overall survival (OS), progression-free survival (PFS), treatment completion, and rate of complete response (CR) was performed.

RESULTS

Twelve studies that involved 2,324 patients with DLBCL were included. Sarcopenia was associated with poor OS and PFS in patients with DLBCL, even after adjusting for confounders. Patients with sarcopenia had lower rates of CR and treatment completion than patients without sarcopenia.

CONCLUSIONS

Sarcopenia is a negative predictor of prognosis in patients with DLBCL. Additional and prospective studies investigating the diagnostic criteria for sarcopenia are warranted.